Selective serotonin reuptake inhibitors for stroke recovery

<p>Stroke is a major cause of death and disability across the world, with many reviews from the Cochrane Stroke Group providing evidence on the effects of treatments and rehabilitation interventions. In November 2019, the Group published their update of their review of selective serotonin reuptake inhibitors and we asked lead author, Gillian Mead from the University of Edinburgh in Scotland, to tell us more.</p><img src="http://feeds.feedburner.com/~r/PodcastsFromTheCochraneLibrary/~4/kGhr0c2atmc" height="1" width="1" alt=""/>